Two years after reaching R1, Baylor’s research momentum only continues to grow
…t Baylor, is part of a team pursuing a groundbreaking drug to treat hypoxic-ischemic brain injury, which affects approximately 2 in every 1,000 U.S. newborns. Romo provides synthetic chemistry leadership for an international team of researchers pursuing the treatment. Romo’s colleague, Dr. Michael Trakselis, has long studied a DNA enzyme linked to infertility and different forms of cancer. Fifteen years of research has led to a breakthrough — grea…